Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;13(10):638-49.
doi: 10.1089/adt.2015.0003.drrr. Epub 2015 Jul 20.

Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication

Olivia Perwitasari  1 , Xiuzhen Yan  1 , Jason O'Donnell  1   2 , Scott Johnson  1 , Ralph A Tripp  1
Affiliations

Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication

Olivia Perwitasari et al. Assay Drug Dev Technol. 2015 Dec.

Abstract

Influenza A virus (IAV) infection causes seasonal epidemics of contagious respiratory illness that causes substantial morbidity and some mortality. Regular vaccination is the principal strategy for controlling influenza virus, although vaccine efficacy is variable. IAV antiviral drugs are available; however, substantial drug resistance has developed to two of the four currently FDA-approved antiviral drugs. Thus, new therapeutic approaches are being sought to reduce the burden of influenza-related disease. A high-throughput screen using a human kinase inhibitor library was performed targeting an emerging IAV strain (H7N9) in A549 cells. The inhibitor library contained 273 structurally diverse, active cell permeable kinase inhibitors with known bioactivity and safety profiles, many of which are at advanced stages of clinical development. The current study shows that treatment of human A549 cells with kinase inhibitors dinaciclib, flavopiridol, or PIK-75 exhibits potent antiviral activity against H7N9 IAV as well as other IAV strains. Thus, targeting host kinases can provide a broad-spectrum therapeutic approach against IAV. These findings provide a path forward for repurposing existing kinase inhibitors safely as potential antivirals, particularly those that can be tested in vivo and ultimately for clinical use.

PubMed Disclaimer

Figures

<b>Fig. 1.</b>
Fig. 1.
Dose-dependent antiviral efficacy of dinaciclib, flavopiridol, and PIK-75 against influenza H7N9 virus. A549 cells were pretreated with increasing dose (¼-log10 increments) of dinaciclib, flavopiridol, or PIK-75 for 2 h at 37°C. Cells were then infected with influenza A/Anhui/1/13 (H7N9) at MOI of 0.01 in the presence of TPCK-trypsin without removal of inhibitors. At 48 hpi, cells were fixed and stained for viral NP and counterstained with DAPI. (A) Representative immunofluorescence images acquired by Cellomics high-content imaging. (B–D) A percentage of infected cells were quantified using the Cellomics system. IC50 values were determined using the nonlinear regression method in GraphPad Prism and summarized in Table 1. (E–G) Culture supernatants were also collected for virus titration in MDCK cells to determine inhibitors' ability to reduce infectious virus titers. Data are expressed as the mean±SE (n=3). *P<0.05; **P<0.01; ***P<0.001 compared to DMSO-treated cells.
<b>Fig. 2.</b>
Fig. 2.
Dose-dependent antiviral efficacy of dinaciclib, flavopiridol, and PIK-75 against pandemic H1N1 virus. A549 cells were pretreated with an increasing dose (¼-log10 increments) of dinaciclib, flavopiridol, or PIK-75 for 2 h. Cells were then infected with influenza A/California/04/09 (pdmH1N1) at MOI of 0.1 in the presence of TPCK-trypsin without removal of inhibitors. At 48 hpi, cells were fixed and stained for viral NP and counterstained with DAPI. (A) Representative immunofluorescence images acquired by Cellomics high-content imaging. (B–D) A percentage of infected cells were quantified using the Cellomics system. IC50 values were determined using the nonlinear regression method in GraphPad Prism and summarized in Table 1. (E–G) Culture supernatants were also collected for virus titration in MDCK cells to determine inhibitors' ability to reduce infectious virus titers. Data are expressed as the mean±SE (n=3). *P<0.05; **P<0.01; ***P<0.001 compared to DMSO-treated cells.
<b>Fig. 3.</b>
Fig. 3.
Dose-dependent antiviral efficacy of dinaciclib, flavopiridol, and PIK-75 against an influenza H3N2 virus. A549 cells were pretreated with an increasing dose (¼-log10 increments) of dinaciclib, flavopiridol, or PIK-75 for 2 h. Cells were then infected with influenza A/Philippines/2/82-X79 (H3N2) at MOI of 0.1 in the presence of TPCK-trypsin without removal of inhibitors. At 24 hpi, cells were fixed and stained for viral NP and counterstained with DAPI. (A) Representative immunofluorescence images acquired by Cellomics high-content imaging. (B–D) A percentage of infected cells were quantified with the Cellomics system. IC50 values were determined using the nonlinear regression method in GraphPad Prism and summarized in Table 1. (E–G) Culture supernatants were also collected for virus titration in MDCK cells to determine inhibitors' ability to reduce infectious virus titers. Data are expressed as the mean±SE (n=3). *P<0.05; ***P<0.001 compared to DMSO-treated cells.
<b>Fig. 4.</b>
Fig. 4.
Synergistic antiviral effect of kinase inhibitors. (A, B) A549 cells were treated with flavopiridol alone (A; top row), dinaciclib alone (A; first column), or a combination of the two drugs from 0.01 to 1 μM for 2 h. (C, D) Cells were treated with PIK-75 alone (C; top row), dinaciclib alone (C; first column), or a combination of the two drugs from 0.01 to 1 μM for 2 h. Cells were then infected with influenza A/California/04/09 (pdmH1N1) at MOI of 0.1 in the presence of TPCK-trypsin without removal of drugs. At 48 hpi, cells were fixed and immunostained for viral NP and counterstained with DAPI. (A, C) Representative immunofluorescence images acquired by Cellomics high-content imaging. (B, D) A percentage of infected cells were quantified with the Cellomics system from two independent experiments and the values were used to compute synergism (or antagonism) volume using the MacSynergyII algorithm. Horizontal plane (arrow; add.) represents the theoretical additive effect of the drugs. Above-the-plane volume indicates synergism, while below-the-plane volume indicates antagonism. Synergism and antagonism volumes are summarized.
<b>Fig. 5.</b>
Fig. 5.
Synergistic antiviral effect of kinase inhibitor with oseltamivir. A549 cells were treated with DMSO or 0.1, 1, or 10 μg/mL of oseltamivir phosphate in combination with DMSO control, dinaciclib (A, B), flavopiridol (C, D), or PIK-75 (E, F) at 0.01, 0.1, or 1 μM for 2 h. Cells were then infected with influenza A/California/04/09 (pdmH1N1) at MOI of 0.1 in the presence of TPCK-trypsin without removal of drugs. At 48 hpi, virus from the supernatant was titered in MDCK cells. Virus titers from three independent experiments were used to compute synergism (or antagonism) volume using the MacSynergyII algorithm. Virus titer results are expressed as the mean (n=3). *P<0.05; **P<0.01; ***P<0.001 compared to DMSO-treated cells.
<b>Fig. 6.</b>
Fig. 6.
Activity of dinaciclib, flavopiridol, and PIK-75 against oseltamivir-resistant virus. A549 cells were treated with DMSO only, oseltamivir phosphate at 10 μg/mL, dinaciclib, flavopiridol, or PIK-75 at 5 μM for 2 h. Cells were then infected with influenza A/Mississippi/3/01 (H1N1) wild type (wt) (A) or H274Y mutant (B) at MOI of 0.1 in the presence of TPCK-trypsin without removal of drugs. At 48 hpi, virus from the supernatant was titered in MDCK cells. Virus titers are expressed as the mean±SE (n=4). *P<0.05; ***P<0.001; n.s. not significant compared to DMSO-treated cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fiore AE, Uyeki TM, Broder K, et al. : Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1–62 - PubMed
    1. Hoyert DL, Kung HC, Smith BL: Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005;53:1–48 - PubMed
    1. Podewils LJ, Liedtke LA, McDonald LC, et al. : A national survey of severe influenza-associated complications among children and adults, 2003–2004. Clin Infect Dis 2005;40:1693–1696 - PubMed
    1. Gao R, Cao B, Hu Y, et al. : Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368:1888–1897 - PubMed
    1. Krammer F, Palese P: Universal influenza virus vaccines: need for clinical trials. Nat Immunol 2014;15:3–5 - PubMed

Publication types

MeSH terms

LinkOut - more resources